At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody.
Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma
26th June 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now